Immunic, inc. announces pricing of oversubscribed $65 million underwritten public offering

New york , may 29, 2025 /prnewswire/ -- immunic, inc. ("immunic" or the "company") (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of (i) pre-funded warrants to purchase shares of common stock (the "pre-funded warrants"), (ii) series a warrants to purchase shares of common stock (or pre-funded warrants) (the "series a warrants"), and (iii) series b warrants to purchase shares of common stock (or pre-funded warrants) (the "series b warrants"). the combined public offering price of one pre-funded warrant, one series a warrant, and one series b warrant, which are being sold together but are immediately seperable, is $0.7499.
IMUX Ratings Summary
IMUX Quant Ranking